Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Predictors of ESA failure in patients with LR-MDS with severe anemia

Matteo Della Porta • 13 Jun 2023
EHA 2023
Myelodysplastic Syndromes ESA

Matteo Della Porta, MD, Humanitas University and Research Hospital, Milan, Italy, discusses the biomarkers associated with erythropoiesis stimulating agent (ESA) failure in patients with lower-risk myelodysplastic syndromes (MDS) with severe anemia, This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Matteo Della Porta

3:46
Current and emerging treatment options for LR-MDS-associated anemia following ESA failure
Matteo Della Porta • 13 Jun 2023
1:47
The COMMANDS study: luspatercept versus epoetin alfa for ESA-naïve lower-risk MDS-associated anemia
Matteo Della Porta • 13 Jun 2023
5:30
COMMANDS: luspatercept vs epoetin alfa for anemia in ESA-naive LR-MDS
Matteo Della Porta • 9 Jun 2023
3:35
Real-world validation of the value of the IPSS-M for prognostication in patients with MDS
Matteo Della Porta • 27 May 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals